相关实验视频

Updated: Jan 14, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

设计,合成和生物评估的2-phenylthiazole CYP51 抑制剂的设计,合成和生物评估

Kejian Li¹, Guoqi Zhang¹, Wenzhan Hao¹

¹Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District Shenyang 110016 PR China medchemzhao@163.com.

RSC medicinal chemistry

|October 23, 2025

概括

新型抗真菌化合物B9对敏感和耐药的真菌菌株具有较低的细胞毒性表现出强烈的活性. 这项研究强调了B9作为开发针对侵入性真菌感染的新治疗方法的有希望的候选人.

科学领域:

药用化学医学化学
菌类学菌类学是指菌类学.
药物发现药物发现药物发现

背景情况:

真菌病原体对全球健康构成重大威胁,导致具有高发病率和死亡率的侵入性感染.
现有的抗真菌疗法面临着耐药性和毒性挑战,需要开发新型治疗剂.

研究的目的:

设计和合成针对兰醇14α-脱甲基酶 (CYP51) 抗真菌活性的新型2-乙衍生物.
确定一种化合物,对敏感和耐药的真菌菌株有强烈的疗效,具有有利的类似药物的特性.

主要方法:

基于主要CYP51抑制剂 (SCZ-14) 的合理药物设计策略.
合成和结构优化27种新型二乙醇衍生物.
抗真菌活性查,细胞毒性评估,药物相似性预测和分子动力学研究.

主要成果:

化合物B9对7种敏感的真菌菌株表现出强烈的抑制作用,对6种对可纳耐药菌株表现出适度的活性.
根据预测软件,B9化合物表现出低细胞毒性和有利的类似药物的特性.
分子动力学研究支持B9化合物作为治疗剂的潜力.

结论:

化合物B9是一种有前途的新型抗真菌剂,具有广泛的活性和良好的安全性.
开发的2-乙衍生物,特别是B9,需要进一步研究以对抗侵入性真菌感染的临床开发.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...